Literature DB >> 2882732

Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens.

D L Stevens, B M Laine, J E Mitten.   

Abstract

The treatment of experimental gas gangrene caused by Clostridium perfringens was investigated by using combinations of antimicrobial agents. This study demonstrated that rifampin, penicillin, metronidazole, and clindamycin were all bactericidal against standard inocula (10(5) to 10(6) CFU). These antimicrobial agents were then administered to mice beginning 30 min after intramuscular injection of 10(9) CFU of C. perfringens type A. The highest doses used produced levels of drug in blood which exceeded the MIC by at least a factor of 40. In addition, other groups of mice received monotherapy at full dose or one-fourth full dose or combination antimicrobial therapy at full or one-fourth full dose. Among the single and combination antimicrobial treatments, metronidazole alone, clindamycin alone, and clindamycin plus penicillin were the most efficacious (P less than 0.05). Although the survival of mice treated with clindamycin plus penicillin was greater than that of mice treated with clindamycin alone, the difference did not reach statistical significance (P greater than 0.05). In contrast, mice treated with a combination of metronidazole and penicillin demonstrated greater mortality than those treated with metronidazole alone (P less than 0.05). In summary, combination antimicrobial therapy of experimental C. perfringens infection did not improve survival compared to that achieved with metronidazole or clindamycin alone, and some combinations significantly reduced survival (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2882732      PMCID: PMC174712          DOI: 10.1128/AAC.31.2.312

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Nutritional factors concerned with growth and lecithinase production by Clostridium perfringens.

Authors:  L G JAYKO; H C LICHSTEIN
Journal:  J Infect Dis       Date:  1959 Mar-Apr       Impact factor: 5.226

2.  Clostridial myonecrosis ('gas gangrene') during cephalosporin prophylaxis.

Authors:  J A Mohr; W Griffiths; R Holm; C Garcia-Moral; D J Flournoy
Journal:  JAMA       Date:  1978-02-27       Impact factor: 56.272

3.  Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen.

Authors:  F J Demello; J J Haglin; C R Hitchcock
Journal:  Surgery       Date:  1973-06       Impact factor: 3.982

4.  Formation of phospholipase C and theta-haemolysin in pre-reduced media in batch anc continuous culture of Clostridium perfringens type A.

Authors:  C E Nord; R Möllby; C Smyth; T Wadström
Journal:  J Gen Microbiol       Date:  1974-09

5.  Gas gangrene in a metropolitan community.

Authors:  P W Brown; P B Kinman
Journal:  J Bone Joint Surg Am       Date:  1974-10       Impact factor: 5.284

6.  Prevention and treatment of gas gangrene.

Authors:  W A Altemeier; W D Fullen
Journal:  JAMA       Date:  1971-08-09       Impact factor: 56.272

7.  Successful prophylaxis of gas gangrene of the high-velocity missile wound in sheep.

Authors:  M S Owen-Smith; J M Matheson
Journal:  Br J Surg       Date:  1968-01       Impact factor: 6.939

8.  Susceptibility of Clostridium perfringens isolated from human infections to twenty antibiotics.

Authors:  J D Schwartzman; L B Reller; W L Wang
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

9.  Gas gangrene and related infection: classification, clinical features and aetiology, management and mortality. A report of 88 cases.

Authors:  S G Darke; A M King; W K Slack
Journal:  Br J Surg       Date:  1977-02       Impact factor: 6.939

10.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

View more
  12 in total

1.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

2.  Mycotic aneurysm caused by Clostridium septicum in a patient with colorectal cancer.

Authors:  Winesh Ramphal; Niels J Raaijmakers; Marjolein van der Klift; Jan H Wijsman; Jan A J W Kluytmans; Eelco J Veen
Journal:  Infection       Date:  2018-05-29       Impact factor: 3.553

3.  Clostridial Infections in Children: Spectrum and Management.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2015-11       Impact factor: 3.725

4.  Clostridial myonecrosis: new insights in pathogenesis and management.

Authors:  Amy E Bryant; Dennis L Stevens
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

5.  Wound Infection with Multi-Drug Resistant Clostridium Perfringens: A Case Study.

Authors:  R Khandia; N Puranik; D Bhargava; N Lodhi; B Gautam; K Dhama
Journal:  Arch Razi Inst       Date:  2021-11-30

6.  Life-threatening clostridial sepsis in a postmenopausal patient with degenerating uterine leiomyoma.

Authors:  Christopher S Bryant; Latoya Perry; Jay P Shah; Sanjeev Kumar; Gunter Deppe
Journal:  Case Rep Med       Date:  2010-05-30

Review 7.  Bacterial, fungal, parasitic, and viral myositis.

Authors:  Nancy F Crum-Cianflone
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  Molecular genetics and pathogenesis of Clostridium perfringens.

Authors:  J I Rood; S T Cole
Journal:  Microbiol Rev       Date:  1991-12

9.  Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection.

Authors:  Yee Gyung Kwak; Seong Ho Choi; Tark Kim; Seong Yeon Park; Soo Hong Seo; Min Bom Kim; Sang Ho Choi
Journal:  Infect Chemother       Date:  2017-12

10.  Uterine Clostridium perfringens infection related to gynecologic malignancy.

Authors:  Kevin M Kremer; Megan E McDonald; Michael J Goodheart
Journal:  Gynecol Oncol Rep       Date:  2017-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.